Login to Your Account

Vertex Bolsters HCV Position with Potential $1.5B+ Alios Deal

By Tom Wall

Tuesday, June 14, 2011
Vertex Pharmaceuticals Inc. positioned itself to expand the multi-billion dollar sales forecasts for recently approved hepatitis C virus (HCV) drug Incivek (telaprevir) with a potential $1.5 billion deal with privately held Alios BioPharma Inc., of South San Francisco, for worldwide rights to preclinical nucleotide analogues ALS-2200 and ALS-2158.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription